Product Data Sheet

Product Name: (±)-Talinolol
Cat. No.: GC15087

Chemical Properties

Cas. No.	57460-41-0		
Chemical Name	N-cyclohexyl-N'-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-urea		
SMILES	O=C(NC1CCCCC1)NC2=CC=C(OCC(O)CNC(C)(C)C)C=C2		
Formula	$C_{20}H_{33}N_3O_3$	M.Wt	363.5
Solubility	≤10mg/ml in ethanol;15mg/ml in DMSO;30mg/ml in dimethyl formamide	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	(±)-Talinolol		

Background

(±)-Talinolol is a selective β1 adrenoceptor antagonist with cardioprotective and antihypertensive activity.

β adrenoceptor antagonist is a class of medications that are particularly used to manage cardiac arrhythmias, and to protect the heart from a second heart attack after a first heart attack.

By blocking β1-adrenergic receptors, (±)-talinolol delays the conduction of stimuli in the AV node, reduces the sino-atrial conduction time, and impedes the sinus node automaticity [1]. Pharmacokinetic data of the time course of plasma concentrations following intravenous infusion of 30 mg (±)-Talinolol revealed that the peak serum concentration (Cmax), the area under the serum concentration-time curve (AUC), and terminal elimination halflife (t1/2) were 631±95 ng/ml, 1433±153 ng×h/ml, and 10.6±3.3 h, respectively. Pharmacokinetic data of the time course of plasma

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

concentrations following oral administration of 50 mg (±)-Talinolol revealed that the Cmax, the AUC, and the t1/2 were 168±67 ng/ml, 1321±382 ng×h/ml, and 11.9±2.4 h, respectively [2].

References:

[1] Abmann I. The actions of talinolol, a β1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction[J]. Current Medical Research and Opinion, 2008, 13(6): 325-342.

[2] Trausch B, Oertel R, Richter K, et al. Disposition and bioavailability of the β1-adrenoceptor antagonist talinolol in man[J]. Biopharmaceutics & Drug Disposition, 1995, 16(5): 403-414.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA